ABVC Biopharma Inc
ABVC2.190USD
+0.150+7.35%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
52.98MMarket Cap
LossP/E TTM
More Details of ABVC Biopharma Inc Company
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products and technologies to combat various diseases. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It also focuses on the development of new drugs and medical devices derived from plants.
ABVC Biopharma Inc Info
Ticker SymbolABVC
Company nameABVC Biopharma Inc
IPO dateNov 09, 2004
CEOPatil (Uttam Yashwant)
Number of employees16
Security typeOrdinary Share
Fiscal year-endNov 09
Address44370 Old Warm Springs Blvd
CityFREMONT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94538-6148
Phone15106680881
Websitehttps://abvcpharma.com/
Ticker SymbolABVC
IPO dateNov 09, 2004
CEOPatil (Uttam Yashwant)
Company Executives of ABVC Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Shuling Jiang
Ms. Shuling Jiang
Director
Director
1.00M
+3.82%
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Chief Scientific Officer, Chief Strategy Officer, Director
Chief Scientific Officer, Chief Strategy Officer, Director
375.99K
-11.15%
Mr. Eugene Jiang
Mr. Eugene Jiang
Chairman of the Board, Chief Business Officer
Chairman of the Board, Chief Business Officer
131.16K
--
Mr. Yoshinobu Odaira
Mr. Yoshinobu Odaira
Independent Director
Independent Director
57.76K
--
Dr. Chang-Jen Jiang, M.D.
Dr. Chang-Jen Jiang, M.D.
Director
Director
42.03K
-0.12%
Dr. Tsang Ming Jiang, Ph.D.
Dr. Tsang Ming Jiang, Ph.D.
Director
Director
41.99K
--
Ms. Yen-Hsin Chou
Ms. Yen-Hsin Chou
Independent Director
Independent Director
41.96K
--
Ms. Norimi Sakamoto
Ms. Norimi Sakamoto
Independent Director
Independent Director
41.85K
--
Ms. Hsin-Hui Miao
Ms. Hsin-Hui Miao
Independent Director
Independent Director
41.51K
-13.66%
Mr. Yu- Min (Francis) Chung
Mr. Yu- Min (Francis) Chung
Independent Director
Independent Director
41.39K
-1.33%
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Shuling Jiang
Ms. Shuling Jiang
Director
Director
1.00M
+3.82%
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Chief Scientific Officer, Chief Strategy Officer, Director
Chief Scientific Officer, Chief Strategy Officer, Director
375.99K
-11.15%
Mr. Eugene Jiang
Mr. Eugene Jiang
Chairman of the Board, Chief Business Officer
Chairman of the Board, Chief Business Officer
131.16K
--
Mr. Yoshinobu Odaira
Mr. Yoshinobu Odaira
Independent Director
Independent Director
57.76K
--
Dr. Chang-Jen Jiang, M.D.
Dr. Chang-Jen Jiang, M.D.
Director
Director
42.03K
-0.12%
Dr. Tsang Ming Jiang, Ph.D.
Dr. Tsang Ming Jiang, Ph.D.
Director
Director
41.99K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Nov 14
Updated: Fri, Nov 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Jiang (Shuling)
4.13%
YuanGene, Corp
3.41%
Jiang (Tsung-Shann)
1.55%
The Vanguard Group, Inc.
1.10%
Geode Capital Management, L.L.C.
0.77%
Other
89.04%
Shareholders
Shareholders
Proportion
Jiang (Shuling)
4.13%
YuanGene, Corp
3.41%
Jiang (Tsung-Shann)
1.55%
The Vanguard Group, Inc.
1.10%
Geode Capital Management, L.L.C.
0.77%
Other
89.04%
Shareholder Types
Shareholders
Proportion
Individual Investor
7.95%
Corporation
3.41%
Investment Advisor
1.34%
Investment Advisor/Hedge Fund
1.17%
Hedge Fund
0.61%
Venture Capital
0.10%
Other
85.41%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
23
785.43K
3.34%
--
2025Q3
24
785.43K
3.45%
+417.95K
2025Q2
21
367.48K
3.90%
-15.11K
2025Q1
23
382.59K
6.37%
-443.49K
2024Q4
23
504.32K
4.97%
+76.07K
2024Q3
24
428.25K
4.88%
+61.75K
2024Q2
25
366.50K
6.03%
-34.07K
2024Q1
23
400.57K
5.13%
-148.69K
2023Q4
23
256.82K
6.23%
-119.98K
2023Q3
25
376.80K
4.62%
+317.95K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Jiang (Shuling)
1.00M
4.26%
+36.89K
+3.82%
Apr 28, 2025
YuanGene, Corp
829.70K
3.52%
--
--
May 27, 2025
Jiang (Tsung-Shann)
375.99K
1.6%
-47.17K
-11.15%
Apr 28, 2025
The Vanguard Group, Inc.
111.53K
0.47%
+64.59K
+137.57%
Jun 30, 2025
Geode Capital Management, L.L.C.
110.50K
0.47%
+6.02K
+5.76%
Jun 30, 2025
Jiang (Eugene)
131.16K
0.56%
--
--
Jul 10, 2025
Renaissance Technologies LLC
41.71K
0.18%
+41.71K
--
Jun 30, 2025
State Street Investment Management (US)
12.90K
0.05%
--
--
Jun 30, 2025
Patil (Uttam)
72.43K
0.31%
--
--
Apr 28, 2025
Odaira (Yoshinobu)
57.76K
0.25%
--
--
Apr 28, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 24, 2023
Merger
10→1
Jul 24, 2023
Merger
10→1
Jul 24, 2023
Merger
10→1
Jul 24, 2023
Merger
10→1
Date
Type
Ratio
Jul 24, 2023
Merger
10→1
Jul 24, 2023
Merger
10→1
Jul 24, 2023
Merger
10→1
Jul 24, 2023
Merger
10→1
FAQs
Who are the top five shareholders of ABVC Biopharma Inc?
The top five shareholders of ABVC Biopharma Inc are:
Jiang (Shuling) holds 1.00M shares, accounting for 4.26% of the total shares.
YuanGene, Corp holds 829.70K shares, accounting for 3.52% of the total shares.
Jiang (Tsung-Shann) holds 375.99K shares, accounting for 1.60% of the total shares.
The Vanguard Group, Inc. holds 111.53K shares, accounting for 0.47% of the total shares.
Geode Capital Management, L.L.C. holds 110.50K shares, accounting for 0.47% of the total shares.
Jiang (Shuling) holds 1.00M shares, accounting for 4.26% of the total shares.
YuanGene, Corp holds 829.70K shares, accounting for 3.52% of the total shares.
Jiang (Tsung-Shann) holds 375.99K shares, accounting for 1.60% of the total shares.
The Vanguard Group, Inc. holds 111.53K shares, accounting for 0.47% of the total shares.
Geode Capital Management, L.L.C. holds 110.50K shares, accounting for 0.47% of the total shares.
What are the top three shareholder types of ABVC Biopharma Inc?
The top three shareholder types of ABVC Biopharma Inc are:
Jiang (Shuling)
YuanGene, Corp
Jiang (Tsung-Shann)
Jiang (Shuling)
YuanGene, Corp
Jiang (Tsung-Shann)
How many institutions hold shares of ABVC Biopharma Inc (ABVC)?
As of 2025Q4, 23 institutions hold shares of ABVC Biopharma Inc, with a combined market value of approximately 785.43K, accounting for 3.34% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.11%.
What is the biggest source of revenue for ABVC Biopharma Inc?
In --, the -- business generated the highest revenue for ABVC Biopharma Inc, amounting to -- and accounting for --% of total revenue.
